HENDERSON NV, Nov. 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – MFusion infuses copper metal ions directly into every sub-bundle of fabric, allowing for 100% copper coverage. The majority of copper textile products currently in the marketplace offer as little as 5% copper coverage.
The Company’s first copper-infused prototype will leverage the natural antimicrobial benefits of copper ions, which have been shown to kill 99.99% of harmful bacteria and viruses. Copper ions are proven pathogen killers and have antimicrobial prevention abilities.
Additionally, these pots will promote healthier plant growth by providing minute amounts of copper leakage over time directly into the growing medium, resulting in healthier plants with larger yields. Plants grown without proper copper in the growing medium result in the plants being copper-deficient and less bountiful harvests.
The BioLife fabric pot prototype has been in development for over a year, with the stated goal of providing a new alternative to gardening consumers who wish to grow plants with environmentally sustainable plant pots instead of the industry’s current offerings which include plastic pots, terra cotta pots, glazed ceramic pots.
The fabric pot is a relatively new product in the gardening plant pot industry, with the first fabric pots being created in 1980. This product has grown slowly but steadily in market share since that time, as more and more gardeners discover the benefits of fabric pots. Fabric pots are especially popular with cannabis cultivators.
BioLife will look to continue to bring new, cutting-edge technology designed to disrupt the gardening industry. The $2.4 billion US home and garden industry has recently shown substantial growth, with gardening activity having surged during the COVID-19 pandemic. Rising interest in home gardening, particularly the growing of vegetables, has also been one of the catalysts towards the recent surge.
About BioLife Sciences Inc.
BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. It’s core business develops, licenses and distributes antimicrobial products and disruptive technologies. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.